Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function

Anetta Undas; Joanna Zdziarska; Teresa Iwaniec; Ewa Stepien; Aleksander B. Skotnicki; Philippe de Moerloose; Marguerite Neerman-Arbez

doi:10.1160/TH08-11-0737

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2009; 101(05): 975-976
DOI: 10.1160/TH08-11-0737

Case Report

Schattauer GmbH

Fibrinogen Krakow: A novel hypo/dysfibrinogenemia mutation in fibrinogen gamma chain (Asn325Ile) affecting fibrin clot structure and function

Authors

Anetta Undas

¹Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
Joanna Zdziarska

²Department of Hematology, Jagiellonian University School of Medicine, Krakow, Poland
Teresa Iwaniec

³Department of Internal Medicine, Jagiellonian University School of Medicine, Krakow, Poland
Ewa Stepien

¹Institute of Cardiology, Jagiellonian University School of Medicine, Krakow, Poland
Aleksander B. Skotnicki

²Department of Hematology, Jagiellonian University School of Medicine, Krakow, Poland
Philippe de Moerloose

⁴Division of Angiology and Haemostasis, University Hospital, Geneva and Faculty of Medicine, Switzerland
Marguerite Neerman-Arbez

⁴Division of Angiology and Haemostasis, University Hospital, Geneva and Faculty of Medicine, Switzerland

⁵Department of Genetic Medicine and Development, University Medical Centre, Geneva, Switzerland

Abstract

Full Text

References

References
1 Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br J Haematol 2001; 114: 249-257.
2 Brennan SO, Fellowes AP, George PM. Molecular mechanisms of hypo- and afibrinogenemia. Ann NY Acad Sci. 2001; 936: 91-100.
3 Vu D, Neerman-Arbez M. Molecular mechanisms accounting for fibrinogen deficiency: from large deletions to intracellular retention of misfolded proteins. J Thromb Haemost 2007; 05 (01) 125-131.
4 Undas A, Celinska-Lowenhoff M, Lowenhoff T. et al. Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease. J Thromb Haemost 2006; 04: 1029-1036.
5 Undas A, Szuldrzynski K, Stepien E. et al. Reduced clot permeability and susceptibility to lysis in patients with acute coronary syndrome: effects of inflammation and oxidative stress. Atherosclerosis 2007; 196: 551-557.
6 Williams S, Fatah K, Ivert T. et al. The effect of acetyl salicylic acid on fibrin gel lysis by tissue plasminogen activator. Blood Coagul Fibrinolysis 1995; 06: 718-725.
7 Neerman-Arbez M, de Moerloose P, Honsberger A. et al. Molecular analysis of the fibrinogen gene cluster in 16 patients with congenital afibrinogenemia: novel truncating mutations in the FGA and FGG genes. Hum Genet 2001; 108: 237-240.
8 Guglielmone HA, Sanchez MC, Abate Daga D. et al. A new heterozygous mutation in gamma fibrinogen gene leading to 326Cys→Ser substitution in fibrinogen Cordoba is associated with defective polymerization and familial hypodysfibrinogenemia. J Thromb Haemost 2004; 02: 352-354.
9 Hamano A, Mimuro J, Aoshima M. et al. Thrombophilic dysfibrinogen Tokio V with the amino acid substitution of γ Ala327Thr: formation of fragile but fibrinolysis-resistant fibrin clots and its relevance to arterial thromboembolism. Blood 2004; 103: 3045-3050.
10 Meyer M, Franke K, Richter W. et al. New molecular defects in the gamma subdomain of fibrinogen D-domain in four cases of hypodysfibrinogenemia: fibrinogen variants Hannover VI, Homburg VII, Stuttgart and Suhl. Thromb Haemost 2003; 89: 637-646.